Senolytic drug reduces cancer resistance to PD-L1 blockade

Resistance to immune checkpoint inhibitors (ICIs), including anti-PD-L1 therapies, remains a major challenge in cancer treatment, with many patients relapsing despite initial responses. Here, we develop a mathematical model to investigate a mechanism of anti-PD-L1 resistance driven by age-associated senescence of CD8 + T cells, in which senescent T cells ( T s ) secrete VEGF, thereby promoting tumor growth through enhanced vascular support. To counteract this effect, we incorporate the senolytic drug navitoclax (ABT-263), which selectively eliminates senescent T cells, and evaluate the efficacy of combined senolytic–anti-PD-L1 therapy in extending tumor remission. Model predictions are validated against independent murine data involving navitoclax and anti-PD-L1 treatment. The model is used to study different strategies of combining the senolytic drug with anti-PD-L1, in order to maximize the remission time of the combined treatment. The optimal starting time of the treatment with the senolytic drug depends on the senescent-to-functional T cells ratio, T s / T . The paper identifies immune senescence as an important determinant of response to cancer immunotherapy.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-11-19
DOI
https://doi.org/10.1371/journal.pone.0362939
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Senolytic drug reduces cancer resistance to PD-L1 blockade

Avner Friedman, Nourridine Siewe
PLoS ONE
Cancer Immunotherapy and Biomarkers
article

Senolytic drug reduces cancer resistance to PD-L1 blockade

Avner Friedman, Nourridine Siewe
article en

Abstract

Resistance to immune checkpoint inhibitors (ICIs), including anti-PD-L1 therapies, remains a major challenge in cancer treatment, with many patients relapsing despite initial responses. Here, we develop a mathematical model to investigate a mechanism of anti-PD-L1 resistance driven by age-associated senescence of CD8 + T cells, in which senescent T cells ( T s ) secrete VEGF, thereby promoting tumor growth through enhanced vascular support. To counteract this effect, we incorporate the senolytic drug navitoclax (ABT-263), which selectively eliminates senescent T cells, and evaluate the efficacy of combined senolytic–anti-PD-L1 therapy in extending tumor remission. Model predictions are validated against independent murine data involving navitoclax and anti-PD-L1 treatment. The model is used to study different strategies of combining the senolytic drug with anti-PD-L1, in order to maximize the remission time of the combined treatment. The optimal starting time of the treatment with the senolytic drug depends on the senescent-to-functional T cells ratio, T s / T . The paper identifies immune senescence as an important determinant of response to cancer immunotherapy.

PLoS ONEVol. 21(11)
Rochester Institute of Technology (US), The Ohio State University (US)
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon